Current Environment: Production

Sandro Santagata | Medical Services

Languages

  • English

Sandro Santagata | Education

Undergraduate School

Neuroscience

Amherst College

1993

Graduate School

PhD, Molecular Basis of Disease

Mount Sinai Medical School

2002, New York, NY

Medical School

Mount Sinai Medical School

2002, New York, NY

Internship

Mount Sinai Medical School

2003, New York, NY

Residency

Anatomic Pathology

Brigham and Women's Hospital

2005, Boston, MA

Fellowship

Neuropathology

Brigham and Women's Hospital

2007, Boston, MA

Sandro Santagata | Certifications

  • American Board of Pathology (Neuropathology)

Sandro Santagata | Publications

  1. Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer. JCI Insight. 2025 May 06. View Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer. Abstract

  2. ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer. Cancer Res. 2025 Apr 03; 85(7):1183-1198. View ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer. Abstract

  3. Sharing data from the Human Tumor Atlas Network through standards, infrastructure and community engagement. Nat Methods. 2025 Apr; 22(4):664-671. View Sharing data from the Human Tumor Atlas Network through standards, infrastructure and community engagement. Abstract

  4. Transplantation of human kidney organoids elicited a robust allogeneic response in a humanized mouse model. Kidney Int. 2025 Jun; 107(6):1011-1016. View Transplantation of human kidney organoids elicited a robust allogeneic response in a humanized mouse model. Abstract

  5. Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma. Clin Cancer Res. 2025 Mar 17; 31(6):983-992. View Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma. Abstract

  6. Multiomic analysis identifies suppressive myeloid cell populations in human TB granulomas. bioRxiv. 2025 Mar 15. View Multiomic analysis identifies suppressive myeloid cell populations in human TB granulomas. Abstract

  7. Papillary Craniopharyngioma: An Integrative and Comprehensive Review. Endocr Rev. 2025 Mar 11; 46(2):151-213. View Papillary Craniopharyngioma: An Integrative and Comprehensive Review. Abstract

  8. A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma. Sci Transl Med. 2025 Feb 19; 17(786):eadn6274. View A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma. Abstract

  9. cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro Oncol. 2025 Feb 10; 27(2):319-330. View cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Abstract

  10. Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors. Neuro Oncol. 2025 Jan 12; 27(1):195-208. View Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors. Abstract

  11. Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma. Cancer Discov. 2024 Dec 20. View Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma. Abstract

  12. Skin immune-mesenchymal interplay within tertiary lymphoid structures promotes autoimmune pathogenesis in hidradenitis suppurativa. Immunity. 2024 12 10; 57(12):2827-2842.e5. View Skin immune-mesenchymal interplay within tertiary lymphoid structures promotes autoimmune pathogenesis in hidradenitis suppurativa. Abstract

  13. Pilot Trial of Perampanel on Peritumoral Hyperexcitability in Newly Diagnosed High-grade Glioma. Clin Cancer Res. 2024 Dec 02; 30(23):5365-5373. View Pilot Trial of Perampanel on Peritumoral Hyperexcitability in Newly Diagnosed High-grade Glioma. Abstract

  14. Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers. Cancer Discov. 2024 Dec 02; 14(12):2430-2449. View Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers. Abstract

  15. Ovarian cancer-derived IL-4 promotes immunotherapy resistance. Cell. 2024 Dec 26; 187(26):7492-7510.e22. View Ovarian cancer-derived IL-4 promotes immunotherapy resistance. Abstract

  16. Quality control for single-cell analysis of high-plex tissue profiles using CyLinter. Nat Methods. 2024 Dec; 21(12):2248-2259. View Quality control for single-cell analysis of high-plex tissue profiles using CyLinter. Abstract

  17. ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in Cancer. bioRxiv. 2024 Oct 21. View ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in Cancer. Abstract

  18. AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Nature. 2024 Nov; 635(8039):755-763. View AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Abstract

  19. Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma. bioRxiv. 2024 Sep 27. View Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma. Abstract

  20. Integrating spatial profiles and cancer genomics to identify immune-infiltrated mismatch repair proficient colorectal cancers. bioRxiv. 2024 Sep 26. View Integrating spatial profiles and cancer genomics to identify immune-infiltrated mismatch repair proficient colorectal cancers. Abstract

  21. Sharing Data from the Human Tumor Atlas Network through Standards, Infrastructure, and Community Engagement. bioRxiv. 2024 Jun 30. View Sharing Data from the Human Tumor Atlas Network through Standards, Infrastructure, and Community Engagement. Abstract

  22. Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer. NPJ Breast Cancer. 2024 Jun 08; 10(1):42. View Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer. Abstract

  23. Pilot trial of perampanel on peritumoral hyperexcitability and clinical outcomes in newly diagnosed high-grade glioma. medRxiv. 2024 Apr 18. View Pilot trial of perampanel on peritumoral hyperexcitability and clinical outcomes in newly diagnosed high-grade glioma. Abstract

  24. STMND1 is a phylogenetically ancient stathmin which localizes to motile cilia and exhibits nuclear translocation that is inhibited when soluble tubulin concentration increases. Mol Biol Cell. 2024 Jun 01; 35(6):ar82. View STMND1 is a phylogenetically ancient stathmin which localizes to motile cilia and exhibits nuclear translocation that is inhibited when soluble tubulin concentration increases. Abstract

  25. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates. Clin Cancer Res. 2024 Apr 01; 30(7):1281-1292. View Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates. Abstract

  26. Multiplexed 3D Analysis of Immune States and Niches in Human Tissue. bioRxiv. 2024 Mar 28. View Multiplexed 3D Analysis of Immune States and Niches in Human Tissue. Abstract

  27. NAB2::STAT6 fusions and genome-wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors. Brain Pathol. 2024 Nov; 34(6):e13256. View NAB2::STAT6 fusions and genome-wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors. Abstract

  28. Quality Control for Single Cell Analysis of High-plex Tissue Profiles using CyLinter. bioRxiv. 2024 Mar 22. View Quality Control for Single Cell Analysis of High-plex Tissue Profiles using CyLinter. Abstract

  29. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. Neuro Oncol. 2024 03 04; 26(3):458-472. View Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. Abstract

  30. Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma. Curr Treat Options Oncol. 2024 02; 25(2):261-273. View Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma. Abstract

  31. Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity. Nat Commun. 2024 Jan 20; 15(1):633. View Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity. Abstract

  32. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Apr 10; 42(11):1311-1321. View Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer. Abstract

  33. Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ Breast Cancer. 2024 Jan 02; 10(1):2. View Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. Abstract

  34. Comprehensive analysis reveals potential therapeutic targets and an integrated risk stratification model for solitary fibrous tumors. Nat Commun. 2023 11 18; 14(1):7479. View Comprehensive analysis reveals potential therapeutic targets and an integrated risk stratification model for solitary fibrous tumors. Abstract

  35. Cell Spotter (CSPOT): A machine-learning approach to automated cell spotting and quantification of highly multiplexed tissue images. bioRxiv. 2023 Nov 17. View Cell Spotter (CSPOT): A machine-learning approach to automated cell spotting and quantification of highly multiplexed tissue images. Abstract

  36. 2D and 3D multiplexed subcellular profiling of nuclear instability in human cancer. bioRxiv. 2023 Nov 11. View 2D and 3D multiplexed subcellular profiling of nuclear instability in human cancer. Abstract

  37. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med. 2023 Dec; 29(12):3067-3076. View Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Abstract

  38. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer Res. 2023 10 02; 83(19):3284-3304. View Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Abstract

  39. Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. J Clin Oncol. 2023 Dec 20; 41(36):5524-5535. View Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. Abstract

  40. Genomic analysis of spinal meningiomas: correlation with histopathological grade. J Neurosurg Spine. 2023 12 01; 39(6):729-733. View Genomic analysis of spinal meningiomas: correlation with histopathological grade. Abstract

  41. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4. Acta Neuropathol. 2023 09; 146(3):515-525. View A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4. Abstract

  42. Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis. Acta Neuropathol Commun. 2023 07 25; 11(1):122. View Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis. Abstract

  43. Chemical QuantArray: A Quantitative Tool for Mass Spectrometry Imaging. Anal Chem. 2023 08 01; 95(30):11243-11253. View Chemical QuantArray: A Quantitative Tool for Mass Spectrometry Imaging. Abstract

  44. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med. 2023 07 13; 389(2):118-126. View BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. Abstract

  45. High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers. Nat Cancer. 2023 07; 4(7):1036-1052. View High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers. Abstract

  46. Meet the authors: Dr. Clint Allen and Dr. Sandro Santagata. Cancer Cell. 2023 05 08; 41(5):834-836. View Meet the authors: Dr. Clint Allen and Dr. Sandro Santagata. Abstract

  47. Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma. Cancer Cell. 2023 05 08; 41(5):871-886.e10. View Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma. Abstract

  48. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell Rep Med. 2023 04 18; 4(4):101007. View USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Abstract

  49. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Res Sq. 2023 Mar 20. View Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Abstract

  50. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro Oncol. 2023 03 14; 25(3):520-530. View Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Abstract

  51. Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer. Cell. 2023 01 19; 186(2):363-381.e19. View Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer. Abstract

  52. Visinity: Visual Spatial Neighborhood Analysis for Multiplexed Tissue Imaging Data. IEEE Trans Vis Comput Graph. 2023 01; 29(1):106-116. View Visinity: Visual Spatial Neighborhood Analysis for Multiplexed Tissue Imaging Data. Abstract

  53. UnMICST: Deep learning with real augmentation for robust segmentation of highly multiplexed images of human tissues. Commun Biol. 2022 11 18; 5(1):1263. View UnMICST: Deep learning with real augmentation for robust segmentation of highly multiplexed images of human tissues. Abstract

  54. Spatial genomics maps the structure, nature and evolution of cancer clones. Nature. 2022 Nov; 611(7936):594-602. View Spatial genomics maps the structure, nature and evolution of cancer clones. Abstract

  55. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. J Clin Oncol. 2023 01 20; 41(3):618-628. View Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. Abstract

  56. Stitching and registering highly multiplexed whole-slide images of tissues and tumors using ASHLAR. Bioinformatics. 2022 09 30; 38(19):4613-4621. View Stitching and registering highly multiplexed whole-slide images of tissues and tumors using ASHLAR. Abstract

  57. Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function. Science. 2022 09 30; 377(6614):1519-1529. View Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function. Abstract

  58. Spatial transcriptomics. Cancer Cell. 2022 09 12; 40(9):895-900. View Spatial transcriptomics. Abstract

  59. PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors. Mod Pathol. 2022 12; 35(12):1770-1774. View PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors. Abstract

  60. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. Nat Commun. 2022 08 16; 13(1):4814. View Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. Abstract

  61. Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro Oncol. 2022 07 01; 24(7):1140-1149. View Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Abstract

  62. The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution. Cancer Discov. 2022 06 02; 12(6):1518-1541. View The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution. Abstract

  63. A human breast atlas integrating single-cell proteomics and transcriptomics. Dev Cell. 2022 06 06; 57(11):1400-1420.e7. View A human breast atlas integrating single-cell proteomics and transcriptomics. Abstract

  64. A molecularly integrated grade for meningioma. Neuro Oncol. 2022 05 04; 24(5):796-808. View A molecularly integrated grade for meningioma. Abstract

  65. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022 03 18; 375(6586):1254-1261. View Copper induces cell death by targeting lipoylated TCA cycle proteins. Abstract

  66. HSF2 cooperates with HSF1 to drive a transcriptional program critical for the malignant state. Sci Adv. 2022 Mar 18; 8(11):eabj6526. View HSF2 cooperates with HSF1 to drive a transcriptional program critical for the malignant state. Abstract

  67. Temporal and spatial topography of cell proliferation in cancer. Nat Cell Biol. 2022 03; 24(3):316-326. View Temporal and spatial topography of cell proliferation in cancer. Abstract

  68. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun. 2022 03 14; 13(1):1325. View Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Abstract

  69. MITI minimum information guidelines for highly multiplexed tissue images. Nat Methods. 2022 03; 19(3):262-267. View MITI minimum information guidelines for highly multiplexed tissue images. Abstract

  70. Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer. Nat Commun. 2022 02 11; 13(1):835. View Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer. Abstract

  71. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022 01 05; 24(1):101-113. View Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Abstract

  72. Multimodal platform for assessing drug distribution and response in clinical trials. Neuro Oncol. 2022 01 05; 24(1):64-77. View Multimodal platform for assessing drug distribution and response in clinical trials. Abstract

  73. Scope2Screen: Focus+Context Techniques for Pathology Tumor Assessment in Multivariate Image Data. IEEE Trans Vis Comput Graph. 2022 01; 28(1):259-269. View Scope2Screen: Focus+Context Techniques for Pathology Tumor Assessment in Multivariate Image Data. Abstract

  74. MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging. Nat Methods. 2022 03; 19(3):311-315. View MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging. Abstract

  75. Skull Base Tumors: Neuropathology and Clinical Implications. Neurosurgery. 2022 03 01; 90(3):243-261. View Skull Base Tumors: Neuropathology and Clinical Implications. Abstract

  76. Narrative online guides for the interpretation of digital-pathology images and tissue-atlas data. Nat Biomed Eng. 2022 05; 6(5):515-526. View Narrative online guides for the interpretation of digital-pathology images and tissue-atlas data. Abstract

  77. Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell. 2021 09 16; 184(19):4996-5014.e26. View Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Abstract

  78. Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery. NPJ Breast Cancer. 2021 Sep 09; 7(1):116. View Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery. Abstract

  79. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. 2021 09 02; 184(18):4753-4771.e27. View Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Abstract

  80. Prognostication for meningiomas: H3K27me3 to the rescue? Neuro Oncol. 2021 08 02; 23(8):1218-1219. View Prognostication for meningiomas: H3K27me3 to the rescue? Abstract

  81. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nat Cancer. 2021 05; 2(5):498-502. View Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Abstract

  82. Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 06; 11(6):1508-1523. View Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Abstract

  83. HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. Clin Cancer Res. 2021 03 15; 27(6):1706-1719. View HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. Abstract

  84. Sporadic multiple meningiomas harbor distinct driver mutations. Acta Neuropathol Commun. 2021 01 06; 9(1):8. View Sporadic multiple meningiomas harbor distinct driver mutations. Abstract

  85. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021 01; 2(1):66-82. View Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Abstract

  86. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun. 2020 10 21; 8(1):171. View Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Abstract

  87. Minerva: a light-weight, narrative image browser for multiplexed tissue images. J Open Source Softw. 2020; 5(54). View Minerva: a light-weight, narrative image browser for multiplexed tissue images. Abstract

  88. SYLARAS: A Platform for the Statistical Analysis and Visual Display of Systemic Immunoprofiling Data and Its Application to Glioblastoma. Cell Syst. 2020 09 23; 11(3):272-285.e9. View SYLARAS: A Platform for the Statistical Analysis and Visual Display of Systemic Immunoprofiling Data and Its Application to Glioblastoma. Abstract

  89. Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 05 18; 11(1):2543. View Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Abstract

  90. Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathol. 2020 07; 140(1):89-93. View Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Abstract

  91. The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell. 2020 04 16; 181(2):236-249. View The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Abstract

  92. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523. View Mechanisms and therapeutic implications of hypermutation in gliomas. Abstract

  93. A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. Cancer Cell. 2020 05 11; 37(5):705-719.e6. View A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. Abstract

  94. Correction to: An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol. 2020 Apr; 139(4):667. View Correction to: An update on the CNS manifestations of neurofibromatosis type 2. Abstract

  95. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020 04; 52(4):371-377. View Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Abstract

  96. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 03 19; 11(1):1459. View Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Abstract

  97. Telomere length alterations and ATRX/DAXX loss in pituitary adenomas. Mod Pathol. 2020 08; 33(8):1475-1481. View Telomere length alterations and ATRX/DAXX loss in pituitary adenomas. Abstract

  98. Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1. JCO Precis Oncol. 2020; 4:79-90. View Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1. Abstract

  99. HSF1 phase transition mediates stress adaptation and cell fate decisions. Nat Cell Biol. 2020 02; 22(2):151-158. View HSF1 phase transition mediates stress adaptation and cell fate decisions. Abstract

  100. Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer. Sci Data. 2019 12 17; 6(1):323. View Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer. Abstract

  101. Localized Metabolomic Gradients in Patient-Derived Xenograft Models of Glioblastoma. Cancer Res. 2020 03 15; 80(6):1258-1267. View Localized Metabolomic Gradients in Patient-Derived Xenograft Models of Glioblastoma. Abstract

  102. Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nat Protoc. 2019 10; 14(10):2900-2930. View Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Abstract

  103. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2. View Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Abstract

  104. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer. 2019 09 01; 125(17):2910-2914. View Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Abstract

  105. Rapid MALDI mass spectrometry imaging for surgical pathology. NPJ Precis Oncol. 2019; 3:17. View Rapid MALDI mass spectrometry imaging for surgical pathology. Abstract

  106. Author Correction: Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019 Jul; 15(7):757. View Author Correction: Mitochondrial metabolism promotes adaptation to proteotoxic stress. Abstract

  107. Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. Clin Cancer Res. 2019 11 01; 25(21):6392-6405. View Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. Abstract

  108. An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol. 2020 04; 139(4):643-665. View An update on the CNS manifestations of neurofibromatosis type 2. Abstract

  109. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 06 03; 10(1):2400. View Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Abstract

  110. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019 07; 15(7):681-689. View Mitochondrial metabolism promotes adaptation to proteotoxic stress. Abstract

  111. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3. View Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. Abstract

  112. The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. Acta Neuropathol. 2019 02; 137(2):307-319. View The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. Abstract

  113. New molecular targets in meningiomas: the present and the future. Curr Opin Neurol. 2018 12; 31(6):740-746. View New molecular targets in meningiomas: the present and the future. Abstract

  114. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J Natl Cancer Inst. 2018 12 01; 110(12):1328-1341. View Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. Abstract

  115. Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol. 2018; 2018. View Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. Abstract

  116. Updates in prognostic markers for gliomas. Neuro Oncol. 2018 11 09; 20(suppl_7):vii17-vii26. View Updates in prognostic markers for gliomas. Abstract

  117. Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. J Neuropathol Exp Neurol. 2018 10 01; 77(10):877-882. View Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. Abstract

  118. Meningioma transcription factors link cell lineage with systemic metabolic cues. Neuro Oncol. 2018 09 03; 20(10):1331-1343. View Meningioma transcription factors link cell lineage with systemic metabolic cues. Abstract

  119. Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. J Neurooncol. 2018 Nov; 140(2):269-279. View Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. Abstract

  120. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018 11; 136(5):779-792. View DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Abstract

  121. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Elife. 2018 07 11; 7. View Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Abstract

  122. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro Oncol. 2018 07 05; 20(8):1101-1112. View Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. Abstract

  123. Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:148-157. View Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. Abstract

  124. Uncovering the links between systemic hormones and oncogenic signaling in the pathogenesis of meningioma. Ann Oncol. 2018 03 01; 29(3):537-540. View Uncovering the links between systemic hormones and oncogenic signaling in the pathogenesis of meningioma. Abstract

  125. A case of molecularly profiled extraneural medulloblastoma metastases in a child. BMC Med Genet. 2018 01 17; 19(1):10. View A case of molecularly profiled extraneural medulloblastoma metastases in a child. Abstract

  126. Orbital leiomyosarcoma metastasis presenting prior to diagnosis of the primary tumor. Digit J Ophthalmol. 2017; 23(4):22-26. View Orbital leiomyosarcoma metastasis presenting prior to diagnosis of the primary tumor. Abstract

  127. Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS One. 2017; 12(11):e0187908. View Radiographic prediction of meningioma grade by semantic and radiomic features. Abstract

  128. BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol. 2017 Oct 19; 19(11):1447-1456. View BAP1 mutations in high-grade meningioma: implications for patient care. Abstract

  129. Nuclear CRX and FOXJ1 Expression Differentiates Non-Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. Am J Surg Pathol. 2017 Oct; 41(10):1410-1421. View Nuclear CRX and FOXJ1 Expression Differentiates Non-Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. Abstract

  130. Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling. Cell Commun Signal. 2017 09 18; 15(1):34. View Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling. Abstract

  131. Erratum: Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017; 2:26. View Erratum: Genomic landscape of high-grade meningiomas. Abstract

  132. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996. View Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Abstract

  133. Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology. 2017 07 01; 158(7):2284-2291. View Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Abstract

  134. Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017; 2. View Genomic landscape of high-grade meningiomas. Abstract

  135. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545. View Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Abstract

  136. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. NPJ Precis Oncol. 2017; 1(1):5. View Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. Abstract

  137. Fatal Eastern Equine Encephalitis in a Patient on Maintenance Rituximab: A Case Report. Open Forum Infect Dis. 2017; 4(1):ofx021. View Fatal Eastern Equine Encephalitis in a Patient on Maintenance Rituximab: A Case Report. Abstract

  138. Rapid Mass Spectrometry Imaging to Assess the Biochemical Profile of Pituitary Tissue for Potential Intraoperative Usage. Adv Cancer Res. 2017; 134:257-282. View Rapid Mass Spectrometry Imaging to Assess the Biochemical Profile of Pituitary Tissue for Potential Intraoperative Usage. Abstract

  139. Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. Proc Natl Acad Sci U S A. 2017 01 10; 114(2):382-387. View Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. Abstract

  140. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics. Neurosurg Focus. 2016 Dec; 41(6):E3. View Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics. Abstract

  141. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy. Neurosurg Focus. 2016 Dec; 41(6):E2. View Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy. Abstract

  142. Susan Lindquist (1949-2016). Science. 2016 Nov 25; 354(6315):974. View Susan Lindquist (1949-2016). Abstract

  143. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. J Neurosurg. 2017 08; 127(2):438-444. View Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. Abstract

  144. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016 Nov 22; 7(47):76565-76576. View Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Abstract

  145. Treatment of brain metastases in the modern genomic era. Pharmacol Ther. 2017 02; 170:64-72. View Treatment of brain metastases in the modern genomic era. Abstract

  146. Landscape of Genomic Alterations in Pituitary Adenomas. Clin Cancer Res. 2017 Apr 01; 23(7):1841-1851. View Landscape of Genomic Alterations in Pituitary Adenomas. Abstract

  147. Distinct patterns of primary and motile cilia in Rathke's cleft cysts and craniopharyngioma subtypes. Mod Pathol. 2016 12; 29(12):1446-1459. View Distinct patterns of primary and motile cilia in Rathke's cleft cysts and craniopharyngioma subtypes. Abstract

  148. SU-D-207B-02: Early Grade Classification in Meningioma Patients Combining Radiomics and Semantics Data. Med Phys. 2016 Jun; 43(6):3348-3349. View SU-D-207B-02: Early Grade Classification in Meningioma Patients Combining Radiomics and Semantics Data. Abstract

  149. Checkpoint inhibition in meningiomas. Immunotherapy. 2016 06; 8(6):721-31. View Checkpoint inhibition in meningiomas. Abstract

  150. Label-Free Neurosurgical Pathology with Stimulated Raman Imaging. Cancer Res. 2016 06 15; 76(12):3451-62. View Label-Free Neurosurgical Pathology with Stimulated Raman Imaging. Abstract

  151. Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. J Pathol. 2016 Mar; 238(4):584-97. View Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. Abstract

  152. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016 Mar; 48(3):273-82. View MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Abstract

  153. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55. View Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Abstract

  154. Genomic landscape of intracranial meningiomas. J Neurosurg. 2016 09; 125(3):525-35. View Genomic landscape of intracranial meningiomas. Abstract

  155. Case-Based Review: meningioma. Neurooncol Pract. 2016 Jun; 3(2):120-134. View Case-Based Review: meningioma. Abstract

  156. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. Eur J Endocrinol. 2016 Apr; 174(4):R139-44. View ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. Abstract

  157. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst. 2016 Feb; 108(2). View Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Abstract

  158. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177. View Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Abstract

  159. Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. Elife. 2015 Sep 01; 4. View Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. Abstract

  160. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74. View A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Abstract

  161. MALDI mass spectrometry imaging analysis of pituitary adenomas for near-real-time tumor delineation. Proc Natl Acad Sci U S A. 2015 Aug 11; 112(32):9978-83. View MALDI mass spectrometry imaging analysis of pituitary adenomas for near-real-time tumor delineation. Abstract

  162. Profiling of adrenocorticotropic hormone and arginine vasopressin in human pituitary gland and tumor thin tissue sections using droplet-based liquid-microjunction surface-sampling-HPLC-ESI-MS-MS. Anal Bioanal Chem. 2015 Aug; 407(20):5989-98. View Profiling of adrenocorticotropic hormone and arginine vasopressin in human pituitary gland and tumor thin tissue sections using droplet-based liquid-microjunction surface-sampling-HPLC-ESI-MS-MS. Abstract

  163. Intraoperative Magnetic Resonance Imaging in Intracranial Glioma Resection: A Single-Center, Retrospective Blinded Volumetric Study. World Neurosurg. 2015 Aug; 84(2):528-36. View Intraoperative Magnetic Resonance Imaging in Intracranial Glioma Resection: A Single-Center, Retrospective Blinded Volumetric Study. Abstract

  164. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96. View Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Abstract

  165. ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genet. 2015 Jun; 208(6):345-50. View ARID1A and TERT promoter mutations in dedifferentiated meningioma. Abstract

  166. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015 Mar 10; 6(7):4704-16. View Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Abstract

  167. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55. View Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Abstract

  168. Molecular typing of Meningiomas by Desorption Electrospray Ionization Mass Spectrometry Imaging for Surgical Decision-Making. Int J Mass Spectrom. 2015 Feb 01; 377:690-698. View Molecular typing of Meningiomas by Desorption Electrospray Ionization Mass Spectrometry Imaging for Surgical Decision-Making. Abstract

  169. Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun. 2014 Dec 24; 2:167. View Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Abstract

  170. HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):18297-302. View HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. Abstract

  171. Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia. Mod Pathol. 2015 Apr; 28(4):596-606. View Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia. Abstract

  172. Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget. 2014 Nov 15; 5(21):10596-606. View Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Abstract

  173. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92. View Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Abstract

  174. Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy. Expert Rev Anticancer Ther. 2014 Dec; 14(12):1385-9. View Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy. Abstract

  175. Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis. Proc Natl Acad Sci U S A. 2014 Oct 21; 111(42):15184-9. View Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis. Abstract

  176. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy. J Clin Oncol. 2016 Apr 01; 34(10):e87-9. View Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy. Abstract

  177. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell. 2014 Jul 31; 158(3):564-78. View The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Abstract

  178. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11121-6. View Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Abstract

  179. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53. View Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Abstract

  180. Artifacts to avoid while taking advantage of top-down mass spectrometry based detection of protein S-thiolation. Proteomics. 2014 May; 14(10):1152-7. View Artifacts to avoid while taking advantage of top-down mass spectrometry based detection of protein S-thiolation. Abstract

  181. Structure-activity relationships for withanolides as inducers of the cellular heat-shock response. J Med Chem. 2014 Apr 10; 57(7):2851-63. View Structure-activity relationships for withanolides as inducers of the cellular heat-shock response. Abstract

  182. Atypical presentation of cerebral schistosomiasis four years after exposure to Schistosoma mansoni. Epilepsy Behav Case Rep. 2014; 2:80-5. View Atypical presentation of cerebral schistosomiasis four years after exposure to Schistosoma mansoni. Abstract

  183. The master regulator of the cellular stress response (HSF1) is critical for orthopoxvirus infection. PLoS Pathog. 2014 Feb; 10(2):e1003904. View The master regulator of the cellular stress response (HSF1) is critical for orthopoxvirus infection. Abstract

  184. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest. 2014 Feb; 124(2):859-70. View Taxonomy of breast cancer based on normal cell phenotype predicts outcome. Abstract

  185. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr; 16(4):567-78. View Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Abstract

  186. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 Feb; 46(2):161-5. View Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Abstract

  187. Mass spectrometry imaging as a tool for surgical decision-making. J Mass Spectrom. 2013 Nov; 48(11):1178-87. View Mass spectrometry imaging as a tool for surgical decision-making. Abstract

  188. Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging. Sci Rep. 2013 Oct 04; 3:2859. View Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging. Abstract

  189. Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. Sci Transl Med. 2013 Sep 04; 5(201):201ra119. View Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. Abstract

  190. Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science. 2013 Jul 19; 341(6143):1238303. View Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Abstract

  191. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotechnol. 2013 Jul; 31(7):630-7. View Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Abstract

  192. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93. View Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Abstract

  193. Eastern equine encephalitis in children, Massachusetts and New Hampshire,USA, 1970-2010. Emerg Infect Dis. 2013 Feb; 19(2):194-201; quiz 352. View Eastern equine encephalitis in children, Massachusetts and New Hampshire,USA, 1970-2010. Abstract

  194. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar; 45(3):285-9. View Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Abstract

  195. Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proc Natl Acad Sci U S A. 2013 Jan 29; 110(5):1611-6. View Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Abstract

  196. Inhibiting HSP90 to treat cancer: a strategy in evolution. Curr Mol Med. 2012 Nov 01; 12(9):1108-24. View Inhibiting HSP90 to treat cancer: a strategy in evolution. Abstract

  197. Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J Clin Invest. 2012 Oct; 122(10):3742-54. View Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. Abstract

  198. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell. 2012 Aug 03; 150(3):549-62. View HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Abstract

  199. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012; 7(6):e38881. View DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. Abstract

  200. Classifying human brain tumors by lipid imaging with mass spectrometry. Cancer Res. 2012 Feb 01; 72(3):645-54. View Classifying human brain tumors by lipid imaging with mass spectrometry. Abstract

  201. Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chem Biol. 2012 Feb 17; 7(2):340-9. View Using the heat-shock response to discover anticancer compounds that target protein homeostasis. Abstract

  202. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A. 2011 Nov 08; 108(45):18378-83. View High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Abstract

  203. Desorption electrospray ionization then MALDI mass spectrometry imaging of lipid and protein distributions in single tissue sections. Anal Chem. 2011 Nov 15; 83(22):8366-71. View Desorption electrospray ionization then MALDI mass spectrometry imaging of lipid and protein distributions in single tissue sections. Abstract

  204. Relapsing tumefactive lesion in an adult with medulloblastoma previously treated with chemoradiotherapy and stem cell transplant. Pathol Oncol Res. 2012 Apr; 18(2):539-43. View Relapsing tumefactive lesion in an adult with medulloblastoma previously treated with chemoradiotherapy and stem cell transplant. Abstract

  205. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn. 2011 Nov; 13(6):669-77. View Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. Abstract

  206. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011 Mar 29; 6(3):e17948. View BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. Abstract

  207. Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content. J Mol Diagn. 2011 Mar; 13(2):220-32. View Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content. Abstract

  208. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10; 29(11):1424-30. View Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. Abstract

  209. Novel MPZ mutations and congenital hypomyelinating neuropathy. Neuromuscul Disord. 2010 Nov; 20(11):725-9. View Novel MPZ mutations and congenital hypomyelinating neuropathy. Abstract

  210. Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Proc Natl Acad Sci U S A. 2010 Oct 05; 107(40):17385-90. View Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Abstract

  211. Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. Am J Transl Res. 2010 May 16; 2(3):309-15. View Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. Abstract

  212. Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell. 2010 May 28; 141(5):872-83. View Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Abstract

  213. CRX is a diagnostic marker of retinal and pineal lineage tumors. PLoS One. 2009 Nov 20; 4(11):e7932. View CRX is a diagnostic marker of retinal and pineal lineage tumors. Abstract

  214. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009 Nov 18; 4(11):e7887. View Profiling critical cancer gene mutations in clinical tumor samples. Abstract

  215. Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Nat Chem Biol. 2009 Sep; 5(9):655-63. View Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Abstract

  216. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 01; 15(1):330-7. View Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Abstract

  217. Mycosis fungoides with leptomeningeal involvement. J Clin Oncol. 2007 Dec 10; 25(35):5658-61. View Mycosis fungoides with leptomeningeal involvement. Abstract

  218. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol. 2007 Jun; 31(6):836-45. View Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Abstract

  219. Post-irradiation meningioma with sarcoidosis. J Neurooncol. 2007 May; 82(3):271-2. View Post-irradiation meningioma with sarcoidosis. Abstract

  220. Anaplastic variant of medulloblastoma mimicking a vestibular schwannoma. J Neurooncol. 2007 Jan; 81(1):49-51. View Anaplastic variant of medulloblastoma mimicking a vestibular schwannoma. Abstract

  221. Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol. 2006 Dec; 30(12):1613-8. View Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Abstract

  222. Intramedullary neuroma of the cervicomedullary junction. Case report. J Neurosurg Spine. 2006 Oct; 5(4):362-6. View Intramedullary neuroma of the cervicomedullary junction. Case report. Abstract

  223. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005 Jul; 1(1):72-80. View A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. Abstract

  224. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004 Oct 01; 64(19):6854-7. View JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Abstract

  225. FokI requires two specific DNA sites for cleavage. J Mol Biol. 2001 May 25; 309(1):69-78. View FokI requires two specific DNA sites for cleavage. Abstract

  226. G-protein signaling through tubby proteins. Science. 2001 Jun 15; 292(5524):2041-50. View G-protein signaling through tubby proteins. Abstract

  227. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood. 2001 Jan 01; 97(1):81-8. View V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Abstract

  228. Recombinase activating gene enzymes of lymphocytes. Curr Opin Hematol. 2001 Jan; 8(1):41-6. View Recombinase activating gene enzymes of lymphocytes. Abstract

  229. N-terminal RAG1 frameshift mutations in Omenn's syndrome: internal methionine usage leads to partial V(D)J recombination activity and reveals a fundamental role in vivo for the N-terminal domains. Proc Natl Acad Sci U S A. 2000 Dec 19; 97(26):14572-7. View N-terminal RAG1 frameshift mutations in Omenn's syndrome: internal methionine usage leads to partial V(D)J recombination activity and reveals a fundamental role in vivo for the N-terminal domains. Abstract

  230. The genetic and biochemical basis of Omenn syndrome. Immunol Rev. 2000 Dec; 178:64-74. View The genetic and biochemical basis of Omenn syndrome. Abstract

  231. Mutations in conserved regions of the predicted RAG2 kelch repeats block initiation of V(D)J recombination and result in primary immunodeficiencies. Mol Cell Biol. 2000 Aug; 20(15):5653-64. View Mutations in conserved regions of the predicted RAG2 kelch repeats block initiation of V(D)J recombination and result in primary immunodeficiencies. Abstract

  232. Definition of minimal domains of interaction within the recombination-activating genes 1 and 2 recombinase complex. J Immunol. 2000 Jun 01; 164(11):5826-32. View Definition of minimal domains of interaction within the recombination-activating genes 1 and 2 recombinase complex. Abstract

  233. Implication of tubby proteins as transcription factors by structure-based functional analysis. Science. 1999 Dec 10; 286(5447):2119-25. View Implication of tubby proteins as transcription factors by structure-based functional analysis. Abstract

  234. The RAG1/RAG2 complex constitutes a 3' flap endonuclease: implications for junctional diversity in V(D)J and transpositional recombination. Mol Cell. 1999 Dec; 4(6):935-47. View The RAG1/RAG2 complex constitutes a 3' flap endonuclease: implications for junctional diversity in V(D)J and transpositional recombination. Abstract

  235. The RAG1 homeodomain recruits HMG1 and HMG2 to facilitate recombination signal sequence binding and to enhance the intrinsic DNA-bending activity of RAG1-RAG2. Mol Cell Biol. 1999 Oct; 19(10):6532-42. View The RAG1 homeodomain recruits HMG1 and HMG2 to facilitate recombination signal sequence binding and to enhance the intrinsic DNA-bending activity of RAG1-RAG2. Abstract

  236. Molecular cloning and characterization of a mouse homolog of bacterial ClpX, a novel mammalian class II member of the Hsp100/Clp chaperone family. J Biol Chem. 1999 Jun 04; 274(23):16311-9. View Molecular cloning and characterization of a mouse homolog of bacterial ClpX, a novel mammalian class II member of the Hsp100/Clp chaperone family. Abstract

  237. Omenn syndrome: a disorder of Rag1 and Rag2 genes. J Clin Immunol. 1999 Mar; 19(2):87-97. View Omenn syndrome: a disorder of Rag1 and Rag2 genes. Abstract

  238. The effect of Me2+ cofactors at the initial stages of V(D)J recombination. J Biol Chem. 1998 Jun 26; 273(26):16325-31. View The effect of Me2+ cofactors at the initial stages of V(D)J recombination. Abstract

  239. Partial V(D)J recombination activity leads to Omenn syndrome. Cell. 1998 May 29; 93(5):885-96. View Partial V(D)J recombination activity leads to Omenn syndrome. Abstract

  240. The homeodomain region of Rag-1 reveals the parallel mechanisms of bacterial and V(D)J recombination. Cell . 1996; 87(2):263-276.

  241. Studies on the Physiology and Plasticity of the Binocular Visual Pathway in the Frog, Rana pipiens. 1993.

BESbswy